• Skip to primary navigation
  • Skip to main content

PEPTIDES - LATEST HOT 🔥 INFO

Peptide News and Research

  • Home
  • Podcast
  • Hot 🔥 Articles
  • About Us
    • Who We Are
    • Privacy Policy
  • Partners

Differences Between Semaglutide and Tirzepatide

September 11, 2024 Dr. Nikki Leave a Comment

The Peptide Podcast

Two of the most promising treatments for obesity in recent years are semaglutide, a GLP-1 agonist, and tirzepatide, a dual GLP-1/GIP agonist. These peptides have garnered attention for their impressive efficacy in weight loss and metabolic improvement, but they differ in their mechanisms, dosing, side effects, and outcomes. In this podcast, we’ll explore how these peptides compare.

Semaglutide and tirzepatide work in similar but slightly different ways for weight loss

Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that is naturally released by the gut in response to food. GLP-1 helps regulate appetite by increasing the feeling of fullness (satiety), slowing gastric emptying, and reducing the body’s insulin resistance. It also stimulates insulin secretion, which helps control blood sugar levels, making it useful not only for weight loss but also for managing type 2 diabetes.

Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another hormone involved in insulin secretion, but it also plays a role in fat metabolism. By engaging both receptors, tirzepatide has a dual/additive impact: it not only boosts insulin sensitivity and appetite suppression (similar to semaglutide) but also enhances the body’s ability to process fat and use it for energy — providing an added benefit for weight loss and metabolic health.

Tirzepatide may result in greater weight loss compared with semaglutide

Semaglutide has been shown to reduce body weight by 10-15% in most clinical trials, with some patients achieving even greater weight loss (up to 17% of total body weight). Additionally, it has proven effective in reducing blood glucose levels and improving insulin sensitivity, making it a great option for patients with type 2 diabetes and obesity.

Tirzepatide has shown superior weight loss efficacy, with reductions of up to 20-25% of body weight in clinical trials. Its dual action on GLP-1 and GIP receptors may explain this enhanced efficacy. It also offers significant improvements in metabolic markers, including better glucose control and insulin sensitivity, which can especially benefit patients with obesity-related metabolic disorders (e.g., type 2 diabetes and polycystic ovary syndrome)

Semaglutide and tirzepatide have different doses

Semaglutide is typically administered as a once-weekly injection. The dosing for weight loss starts at 0.25 mg per week and gradually increases in 4-week intervals to a maintenance dose of 2.4 mg per week. The gradual titration helps minimize side effects such as nausea. Sometimes, the semaglutide dose may be increased sooner than the 4-week interval based on the person’s response to the peptide.

Tirzepatide is also administered as a once-weekly injection. The dosing for weight loss starts at 2.5 mg per week and gradually increases to a maintenance dose of 5 mg to 7.5 mg per week, with some people requiring higher doses (10 mg, 12.5 mg, or 15 mg). The dose is generally increased based on patient tolerance, similar to semaglutide but shouldn’t be increased sooner than 4 weeks. 

Semaglutide and tirzepatide have similar side effects

Common side effects of semaglutide include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Headache
  • Tiredness

These stomach-related side effects are usually temporary and go away on their own as the body adjusts to the medication. However, some people may experience more severe symptoms, necessitating a lower dose.

Tirzepatide shares many of the same side effects as semaglutide, including:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Burping
  • Flatulence
  • Indigestion

Keep in mind:  Tirzepatide’s side effects can sometimes be more pronounced, particularly during the dose-escalation phase. Some patients may also experience signs of low blood sugar, especially if used in combination with insulin.

Semaglutide may be a better option if you have heart disease

In March 2024, semaglutide received additional FDA approval for reducing cardiovascular risk in adults with heart disease who are overweight or obese. Clinical studies show that semaglutide reduced the risk of major adverse cardiovascular events—such as heart attack, stroke, or cardiovascular death—by 20%.

Tirzepatide is currently being studied for similar cardiovascular benefits.

Semaglutide and tirzepatide may have benefits for other health conditions

Semaglutide has demonstrated positive outcomes in certain people with heart failure, and a recent study suggests potential kidney-related benefits for those with heart disease. It is also being studied as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis, a condition caused by excess fat accumulation in the liver.

Tirzepatide has shown promise for individuals with moderate-to-severe obstructive sleep apnea and may receive approval for this use by late 2024. Additionally, it is under investigation for potential benefits in cardiovascular risk reduction, heart failure, MASH, and chronic kidney disease.

In summary:

  • Mechanism: Semaglutide targets only GLP-1, while tirzepatide activates both GLP-1 and GIP receptors.
  • Efficacy: Tirzepatide has demonstrated superior weight loss results compared to semaglutide.
  • Side Effects: Both drugs have similar stomach-related side effects, though tirzepatide may be more potent and have a higher incidence of certain symptoms.
  • Dosing: Both are administered as weekly injections, but their doses differ.

Ultimately, the choice between these therapies will depend on individual patient needs, tolerance, and response to treatment. 

Someone might choose tirzepatide over semaglutide for weight loss due to its greater efficacy in achieving higher levels of weight reduction and its dual mechanism that offers additional metabolic benefits. Others choose to switch from semaglutide to tirzepatide if they hit a weight loss plateau despite changing nutrition and physical activity habits.

When it comes down to it, it’s a personal choice. 

Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week!

We’re huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it’s a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey. 

Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

Filed Under: Podcast Tagged With: glp1, peptides, semaglutide, tirzepatide, weightloss

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Copyright © 2025

PEPTIDES

The contents of this website, such as text, graphics, images, and other material contained on the website (“Content”) are for informational purposes. Our site is not intended to be a substitute for professional medical advice, diagnosis, or treatment from a licensed healthcare professional. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

Never disregard professional medical advice or delay in seeking it because of something you have read on this website.